Biomea Fusion (BMEA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Covalent Small Moleculessrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 65/100 (HIGH), 4.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 19.6% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Biomea Fusion Announces Termination of Proposed Public Offering of Securities
- Biomea Fusion Announces Proposed Public Offering of Securities
- After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
- Biomea Fusion to Participate in Upcoming Investor Conferences
- Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
- Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
- Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
- Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. — J Immunother Cancer 2026 Sep 7 PMID 42705861
- Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception. — Cardiovasc Diabetol 2026 Aug 26 PMID 42649514
- Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. — Circulation 2026 Sep 15 PMID 42610271
- Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. — Nat Med 2026 Aug PMID 42581230
- Factors Associated With Progression From Level 1 to Level 2 Sensor-Detected Hypoglycaemia in People With Type 1 and Insulin-Treated Type 2 Diabetes: A Post Hoc Analysis From the Hypo-METRICS Study. — Diabetes Obes Metab 2026 Oct PMID 42552225
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Biomea Fusion.
Full BMEA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.